


Supporting Information


Ruthenium(II) *p*-cymene complex of pyridine-2-carboxaldehyde and 2-amino benzothiazole based ligand: A cytoselective and *in vitro* live cell imaging agent†

Anuja PK, Priyankar Paira*


¹H NMR spectra of complex RuL1




ESI-MS of complex RuL1




IR spectra of RuL1




¹H NMR of complex RuL2




ESI-MS of complex RuL2





IR spectra of RuL2




¹H NMR of RuL3




ESI-MS of complex RuL3




¹H NMR of RuL4




ESI-MS of complex RuL4




IR spectra of complex RuL4




¹H NMR of RuL5



ESI-MS of complex RuL5



IR spectra of RuL5






Fig. S1 *In vitro* dose–response curves for complexes (RuL1–RuL5) against HEK-293 cells treated under 48 h CO_2 incubation.






Fig. S2. (a) UV-Vis absorption spectrum of complex **RuL3** in absence and in presence of 10-100 μ M of ct-DNA in TrisHCl buffer (pH 7.8, T = 25 °C). (b) plot of $[DNA]/(\epsilon_a - \epsilon_f)$ vs $[DNA]$. (c) Ethidium bromide fluorescence quenching study with complex **RuL3**. (d) Stern Volmer plot of I_0/I vs. $[RuL3]$









(a)



(b)

Fig. S3. (a) Ethidium bromide fluorescence quenching study with control DNA intercalator $[\text{Ru}(\text{bpy})_2(\text{dppz})]^{2+}$ (b) Stern Volmer plot of I_0/I vs. [control]

Table S1 Comparison of the IC₅₀ values of previously reported Ru-*p*-cymene complexes against cancer cell lines

Complex	IC ₅₀ (μM)			references
	Cell lines			
	HeLa	MCF-7		
	-	2.64		1
	-	18.21		1
	-	7.36		1
	-	7.76-25.42		2
	-	10.2±1.2		3
	-	26-300		4
[[(p- cym)RuCl(HL1)]BF4	-	68±3		4
	3.52±1.7	-		5

References:

1. T. A. Khan, K. Bhar, R. Thirumoorthi, T. Roy, A. K. Sharma, *New J. Chem.*, 2020, 44, 239—257.
2. (a) G. R. Jadhav, S. Sinha, M. Chhabra and P. Paira, *Bioorg. Med. Chem. Lett.*, 2016, 26, 2695–2700. (b) U. Ndagi, N. Mhlongo and M. E. Soliman, *Drug Des., Dev. Ther.*, 2017, 11, 599.
3. F. Hackenberg, H. Müller-Bunz, R. Smith, W. Streciwilk, X. Zhu and M. Tacke, *Organometallics*, 2013, 32, 5551–5560.
4. M. Martínez-Alonso, N. Bustó, F. A. Jaloón, B. R. Manzano, J. M. Leal, A. M. Rodríguez, B. García and G. Espino, *Inorg. Chem.*, 2014, 53, 11274–11288.
5. A Mondal, U Sen, N Roy, V Muthukumar, SK Sahoo, B Bose, P Paira*, *Dalton Transactions* 2021, 50 (3), 979-997